Stay updated on Ixekizumab Efficacy in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Ixekizumab Efficacy in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Ixekizumab Efficacy in Psoriatic Arthritis Clinical Trial page
- CheckyesterdayChange DetectedKey treatment arms and related terminology, along with substantial study-record metadata, were removed from the study page, affecting how the SPIRIT-P1 trial details and its historical record are presented to users.SummaryDifference17%

- Check8 days agoChange DetectedUpdated the Ukraine location entry from Zaporizhzhia, Ukraine, 69600 to Zaporizhzhya, Ukraine, 69600 in the study locations. This clarifies the correct city spelling while keeping the same postal code.SummaryDifference0.0%

- Check16 days agoChange DetectedA new revision tag, Revision: v3.6.4, was added to the page while the previous tag Revision: v3.6.3 was removed. This signals a minor backend/documentation version update and does not alter the study details.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.3, indicating a newer page revision.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study page now indicates that recruitment has ended and adds user-guidance sections such as How to Read a Study Record, Common Questions, and How to Join a Study. The Intervention/Treatment header formatting was standardized and a site revision note (Revision: v3.6.0) was added, replacing the prior v3.5.5.SummaryDifference0.2%

- Check58 days agoChange DetectedThe revision tag updated to Revision: v3.5.5, replacing the previous v3.5.4, indicating a small update to the study record's documentation.SummaryDifference0.0%

Stay in the know with updates to Ixekizumab Efficacy in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixekizumab Efficacy in Psoriatic Arthritis Clinical Trial page.